Myovant Sciences Ltd
NYSE:MYOV
Intrinsic Value
Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one MYOV stock under the Base Case scenario is 6.21 USD. Compared to the current market price of 26.98 USD, Myovant Sciences Ltd is Overvalued by 77%.
Valuation Backtest
Myovant Sciences Ltd
Run backtest to discover the historical profit from buying and selling MYOV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Myovant Sciences Ltd
Current Assets | 386.6m |
Cash & Short-Term Investments | 274.4m |
Receivables | 44m |
Other Current Assets | 68.1m |
Non-Current Assets | 16.9m |
PP&E | 9.6m |
Other Non-Current Assets | 7.3m |
Current Liabilities | 245.8m |
Accounts Payable | 12.2m |
Accrued Liabilities | 90m |
Other Current Liabilities | 143.5m |
Non-Current Liabilities | 715.9m |
Long-Term Debt | 358.7m |
Other Non-Current Liabilities | 357.2m |
Earnings Waterfall
Myovant Sciences Ltd
Revenue
|
379.1m
USD
|
Cost of Revenue
|
-102.3m
USD
|
Gross Profit
|
276.9m
USD
|
Operating Expenses
|
-423.8m
USD
|
Operating Income
|
-146.9m
USD
|
Other Expenses
|
-36.9m
USD
|
Net Income
|
-183.8m
USD
|
Free Cash Flow Analysis
Myovant Sciences Ltd
What is Free Cash Flow?
MYOV Profitability Score
Profitability Due Diligence
Myovant Sciences Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Myovant Sciences Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
MYOV Solvency Score
Solvency Due Diligence
Myovant Sciences Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Myovant Sciences Ltd's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MYOV Price Targets Summary
Myovant Sciences Ltd
Ownership
MYOV Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MYOV Price
Myovant Sciences Ltd
Average Annual Return | 3.8% |
Standard Deviation of Annual Returns | 56.07% |
Max Drawdown | -78% |
Market Capitalization | 2.6B USD |
Shares Outstanding | 97 259 504 |
Percentage of Shares Shorted | 17.9% |
MYOV News
Last Important Events
Myovant Sciences Ltd
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Myovant Sciences Ltd
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company’s two products include ORGOVYX, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The company through its subsidiary, Myovant Sciences GmbH developing supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. The company is developing Relugolix for the treatment of men with advanced prostate cancer. The company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
Contact
IPO
Employees
Officers
The intrinsic value of one MYOV stock under the Base Case scenario is 6.21 USD.
Compared to the current market price of 26.98 USD, Myovant Sciences Ltd is Overvalued by 77%.